MIAMI, March 26, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time.
Peripheral/Endo
Evident Vascular Raises Series B Financing to Advance AI-Powered Intravascular Ultrasound Platform Technology
Funding to accelerate development of next-generation intravascular ultrasound platform and support FDA clearance for U.S. market launch SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new […]
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International. Twelve-month results from the randomized arm of the WAVE trial are scheduled for presentation at the Society of Interventional Radiology’s 50th Annual Scientific Meeting in Nashville, TN. The podium presentation is scheduled for March 30, 2025, during the late-breaking trials session.
Imperative Care Expands Symphony Precision Thrombectomy Portfolio with Purpose-Built Design for the Treatment of Venous Thrombosis
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its Symphony™ 16F Catheter, the company’s latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of […]
Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter
ALISO VIEJO, Calif., March 24, 2025 /PRNewswire/ — Okami Medical announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the SENDERO MAX Delivery Catheter. This milestone expands Okami’s embolization portfolio, which includes the…
First-in-Human Clinical Results for SonoVascular’s SonoThrombectomy™ System Presented at the 2025 Annual Meeting of the American Venous Forum
CHAPEL HILL, N.C., March 18, 2025 /PRNewswire/ — SonoVascular, Inc., a clinical stage medical device company focused on bringing to market its SonoThrombectomy™ System for venous thromboembolism (VTE), a novel treatment solution intended to provide better outcomes for millions of…
Instylla Completes Submission of Premarket Approval Application for Embrace™ Hydrogel Embolic System
BEDFORD, Mass., March 11, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval…
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions
Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ — Today, Shockwave Medical, Inc., part of Johnson…
Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field.